NEW YORK – Roche announced Tuesday it has received CE marking for its Cobas PIK3CA Mutation test for identifying patients with metastatic breast cancer who might benefit the most from phosphoinositide 3-kinase (PI3K) targeted therapy.
NEW YORK – Roche announced Tuesday it has received CE marking for its Cobas PIK3CA Mutation test for identifying patients with metastatic breast cancer who might benefit the most from phosphoinositide 3-kinase (PI3K) targeted therapy.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.